Please use this identifier to cite or link to this item:
https://doi.org/10.1038/srep24786
Title: | KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer | Authors: | Liu, Y.-Z Yang, H Cao, J Jiang, Y.-Y Hao, J.-J Xu, X Cai, Y Wang, M.-R |
Keywords: | antineoplastic agent KRAS protein, human messenger RNA protein p21 tumor marker adult aged Carcinoma, Non-Small-Cell Lung female gene expression regulation genetics human Kaplan Meier method lung tumor male metabolism middle aged mortality prognosis proportional hazards model signal transduction treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung Female Gene Expression Regulation, Neoplastic Humans Kaplan-Meier Estimate Lung Neoplasms Male Middle Aged Prognosis Proportional Hazards Models Proto-Oncogene Proteins p21(ras) RNA, Messenger Signal Transduction Treatment Outcome |
Issue Date: | 2016 | Citation: | Liu, Y.-Z, Yang, H, Cao, J, Jiang, Y.-Y, Hao, J.-J, Xu, X, Cai, Y, Wang, M.-R (2016). KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer. Scientific Reports 6 : 24786. ScholarBank@NUS Repository. https://doi.org/10.1038/srep24786 | Rights: | Attribution 4.0 International | Abstract: | Nowadays, no robust biomarkers have been applied to clinical practice to provide prognostic evaluation of non-small cell lung cancer (NSCLC). This study aims to identify new potential prognostic biomarkers for NSCLC. In the present work, KIAA1522 is screened out from two independent GEO datasets as aberrantly up-regulated gene in NSCLC tissues. We evaluate KIAA1522 expression immunohistochemically in 583 NSCLC tissue samples and paired non-tumor tissues. KIAA1522 displays stronger staining in NSCLC cases than in adjacent normal lung tissues. Importantly, patients with KIAA1522 overexpression had a significantly shorter overall survival compared to those with low expression (P < 0.00001). Multivariate Cox regression analyses show that KIAA1522 is an independent prognostic indicator, even for early-stage NSCLCs (P = 0.00025, HR = 2.317, 95%CI: 1.477-3.635). We also found that high expression of KIAA1522 is a significant risk factor for decreased overall survival of the patients who received platinum-based chemotherapy. Gene set enrichment analysis (GSEA) and functional studies reveal that KIAA1522 is associated with oncogenic KRAS pathways. Taken together, high expression of KIAA1522 can be used as an independent biomarker for predication of poor survival and platinum-resistance of NSCLC patients, and aberrant KIAA1522 might be a new target for the therapy of the disease. | Source Title: | Scientific Reports | URI: | https://scholarbank.nus.edu.sg/handle/10635/178917 | ISSN: | 20452322 | DOI: | 10.1038/srep24786 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_srep24786.pdf | 6.2 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License